Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Kit for predicting curative effect of lucentis for treating age-related macular degeneration

A macular degeneration, ranibizumab technology, used in the determination/inspection of microorganisms, DNA/RNA fragments, recombinant DNA technology, etc.

Inactive Publication Date: 2015-09-09
BEIJING HOSPITAL
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no research results on the relationship between the rs142961510GA / - site of the VEGF-A gene and the efficacy of ranibizumab in the treatment of age-related macular degeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for predicting curative effect of lucentis for treating age-related macular degeneration
  • Kit for predicting curative effect of lucentis for treating age-related macular degeneration
  • Kit for predicting curative effect of lucentis for treating age-related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1: Blood Sample Collection and Genomic DNA Extraction

[0039]1. Cases were selected according to the revised diagnostic criteria in New York in 1984. A total of unrelated AMD patients from Beijing were selected. Among them, 55 patients with good curative effect on age-related macular degeneration treated with ranibizumab were used as the case group (age: 55-80 years old, with an average of 71 years), and 60 patients with poor efficacy in the treatment of age-related macular degeneration with ranibizumab were used as the control group (age: 56-82 years, with an average of 72 years). All subjects were of Han nationality and signed written informed consent. This study was approved by the Beijing Hospital and Beijing Institute of Gerontology Ethical Review Committee, and complied with the World Medical Association Declaration of Helsinki: Ethical Principles for Human Medical Research.

[0040] 2. According to the following method, human genomic DNA was prepared. ①...

Embodiment 2

[0041] Example 2: Identification and Identification of Variation Sites

[0042] The invention adopts PCR-sequencing analysis method to detect the genotype of the +401 site (the allelic site is G / A) in the sixth intron region of the VEGF-A gene. figure 2 It is the sequencing map of the VEGF-A gene variation site.

[0043] 1. Determination of PCR-sequencing primers

[0044] The DNA base sequence (Seq ID №1) near rs142961510GA / - was retrieved from Genebank, and the primer design was completed under Oligo7.0 software. The target fragment is located in the 6th intron region of the VEGF-A gene, with a total length of 806bp. The sense strand F1 (+291bp-+310bp) and the antisense strand R1 (+473bp-+492bp) are determined. The specific primer sequences are as follows:

[0045] F1: 5'-AAAACACAGACTCGCGTTGC-3' (Seq ID NO.2)

[0046] R1: 5'-AGTTTCTAGCTGCCTGCCTG-3' (Seq ID NO.3)

[0047] 2. PCR-sequencing reaction system and conditions

[0048] Amplify a partial fragment of the 6th intr...

Embodiment 3

[0051] Example 3: Correlation between Gene SNP and AMD

[0052] Statistical methods: The Hardy-Weinberg balance test was used to study the group representativeness of the samples. The distribution frequency of alleles and genotypes of VEGF-A gene rs142961510GA / - site between the ranibizumab-treated age-related macular degeneration curative effect case group and the normal control group was calculated by Pearson chi-square test in SPSS17.0 software. The risk OR value and its 95% CI confidence interval for the efficacy of ranibizumab in the treatment of age-related macular degeneration, with P<0.05 as the standard of significant difference.

[0053] Results: The distribution of the genotype and allele frequency of the rs142961510GA / - site on the VEGF-A gene located in the 6p12 region between the cases and the control group is shown in Table 1.

[0054] Table 1 Distribution of genotype and allele frequency of VEGF-A(rs142961510GA / -) locus in case-control group

[0055]

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a kit for predicting the curative effect of lucentis for treating age-related macular degeneration and belongs to the field of biotechnology. A method for predicting the curative effect of lucentis for treating the age-related macular degeneration comprises the following steps: extracting genome DNA of a host cell, measuring the genotype of a sixth intron rs142961510GA / -site of a VEGF-A (vascular endothelial growth factor-A) gene of a subject, and predicting the curative effect of the lucentis for treating age-related macular degeneration on the subject. By using the kit and the method provided by the invention, the susceptivity of the subject to the lucentis for treating the age-related macular degeneration can be predicted by measuring the polymorphism of an AMD related gene VEGF-A, and the method can be used for guiding individualized treatment of the age-related macular degeneration by using the lucentis.

Description

technical field [0001] The invention relates to a kit for predicting the curative effect of ranibizumab in treating age-related macular degeneration, more specifically, predicting the age of a subject for ranibizumab treatment by measuring the polymorphism of AMD-related gene VEGF-A The susceptibility of related macular degeneration, the method can be used to guide the individualized treatment of ranibizumab for age-related macular degeneration, and belongs to the field of biotechnology. Background technique [0002] Age-related macular degeneration (AMD) is the leading cause of blindness in people over the age of 50 in the West. Studies have found that AMD may be related to ultraviolet radiation and trace element deficiency, but the specific etiology remains unclear. Domestic surveys show that the incidence rate of age-related macular degeneration is 15.5%, and its incidence rate increases with age. With the advent of population aging, age-related macular degeneration has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6827C12Q2600/106C12Q2600/156
Inventor 喻晓兵宋爽戴虹杨泽卢颖毅陈彤师自安赵晶岳枚谷潇雅黄剑锋王铮李晓宇王笑雄杨建黄辰晔王越倩
Owner BEIJING HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com